respiratory Archives - Page 5 of 15 -

FREE TO ATTEND

FREE TO ATTEND | Formulation & Drug Delivery Event: Virtual

https://pharmaphorum.com/partner-content/free-to-attend-formulation-drug-delivery-event-virtual/

Market Access/ News/ News

Verona says FDA backs plan to take COPD drug into phase 3

Phil Taylor COPD, inflammation, respiratory, Verona Pharma 0 Comment

More than two years after first saying it would take its lead drug into a pivotal trial, Verona

Verona says FDA backs plan to take COPD drug into phase 3

https://pharmaphorum.com/news/verona-says-fda-backs-plan-to-take-copd-drug-into-phase-3/

Digital/ Market Access/ News/ News/ News/ Top stories

Novartis on point in EU for asthma triple as CHMP backs Enerzair

Phil Taylor asthma, CHMP, Enerzair, GlaxoSmithKline, Novartis, respiratory, Trelegy 0 Comment

Novartis has moved a step closer to EU approval of its three-drug asthma therapy Enerzair Breezhaler, and now

Novartis on point in EU for asthma triple as CHMP backs Enerzair

https://pharmaphorum.com/news/novartis-on-point-in-eu-for-asthma-triple-as-chmp-backs-enerzair/

News/ News/ R&D

Chiesi starts rare diseases division, ahead of potential Fabry disease filing

Richard Staines Chiesi, Fabry disease, Protalix, R&D, Rare diseases, respiratory, Takeda 0 Comment

Italian pharma Chiesi has begun a new rare diseases division as it builds towards a potential commercial launch

Chiesi starts rare diseases division, ahead of potential Fabry disease filing

https://pharmaphorum.com/news/chiesi-starts-rare-diseases-division-as-fabry-treatment/

News/ News/ Patients/ Top stories

FDA clears emergency diagnostic as coronavirus fears mount

Phil Taylor coronavirus, infectious disease, respiratory 0 Comment

The US drugs regulator has approved emergency use of a diagnostic for the strain of coronavirus causing the

FDA clears emergency diagnostic as coronavirus fears mount

https://pharmaphorum.com/news/fda-clears-emergency-diagnostic-as-coronavirus-fears-mount/

Market Access/ News/ News/ News/ Patients

FDA sets June date for latest review of Merck’s last-ditch antibiotic

Phil Taylor antibiotic, Merck & Co, Recarbrio, respiratory 0 Comment

The FDA has started a six-month priority review of Merck & Co/MSD’s triple antibiotic Recarbrio in a new

FDA sets June date for latest review of Merck’s last-ditch antibiotic

https://pharmaphorum.com/news/fda-sets-june-date-for-latest-review-of-mercks-last-ditch-antibiotic/

Market Access/ News/ News

Chasing Mylan, Hikma tries again with rejected generic Advair in US

Phil Taylor Advair, asthma, Chronic Obstructive Pulmonary Disease, generic, GlaxoSmithKline, Hikma, Mylan, respiratory, Sandoz 0 Comment

UK-listed Hikma Pharma has filed a response to the FDA that it hopes will clear the way for

Chasing Mylan, Hikma tries again with rejected generic Advair in US

https://pharmaphorum.com/news/chasing-mylan-hikma-tries-again-with-rejected-generic-advair-in-us/

Market Access/ News/ News

FDA rejection scuppers AZ’s hopes of a COPD triple clash with GSK

Phil Taylor AstraZeneca, Chiesi, COPD, GlaxoSmithKline, respiratory 0 Comment

The FDA has just handed an advantage to GlaxoSmithKline’s triple therapy for chronic obstructive pulmonary disease (COPD) by

FDA rejection scuppers AZ’s hopes of a COPD triple clash with GSK

https://pharmaphorum.com/news/fda-rejection-scuppers-azs-hopes-of-a-copd-triple-clash-with-gsk/

News/ News/ R&D

Novartis announces positive results from asthma combinations

Richard Staines Novartis, R&D, respiratory 0 Comment

Novartis has announced positive results from trials testing its daily fixed dose treatment two-drug combination for people with

Novartis announces positive results from asthma combinations

https://pharmaphorum.com/news/novartis-announces-positive-results-from-asthma-combination-therapies/

Trending

respiratory

Login